PAOG CBD Pharmaceutical Respiratory Treatment Research

0

Sandusky, OH, October 13, 2021 (GLOBE NEWSWIRE) – PAO Group, Inc. (OTC Pink: PAOG) today announced that it has recently encountered a wave of outside interest in the company’s research into pharmaceutical respiratory therapy in CBD.

Last year, the company acquired intellectual property derived from research on CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). Ongoing research targets the treatment of respiratory disorders in support of a pharmaceutical product developed by PAOG under the name RespRx.

PAOG is committed Véristat as a CRO to prepare an IND for the FDA.

In recent times, CBD is increasingly recognized for its benefits for respiratory health. For example:

COPD: Can CBD Help?

The latest information on the implications of CBD Covid

In conjunction with PAOG’s ongoing IND initiative for RespRx and PAOG’s connection with US Patent No. 9,199,960 titled “METHOD AND APPARATUS OF TREATMENT”, PAOG now receives unsolicited contacts expressing interests ranging from investment and partnership in the acquisition.

PAOG is not changing its plans at this point in response to recent interest. The company will continue to develop its pharmaceutical and nutraceutical treatments.

PAOG expects to achieve its first sales of CBD nutraceuticals from the fourth quarter of 2021.

The company confirms that it shipped its first CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (OTC PINK: USMJ).

PAOG plans to announce details of its first CBD nutraceutical product in an upcoming official product launch announcement once the distributor is set up to begin sales and distribution.

PAOG expects revenue to grow quickly after its first CBD nutraceutical product launch, as the company has tracking products lined up to track the first product, adding to the overall sales potential.

The CBD Nutraceuticals Market 2020 was estimated to be worth $ 5.2 billion and is expected to grow to $ 16.4 billion by 2027.

Learn more on the USMJ e-commerce site at www.usmj.com.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements contained in this press release may contain forward-looking information within the meaning of Rule 175 of the Securities Act of 1933 and Rule 3b-6 of the Securities Exchange Act of 1934 and are subject to the safe harbor created by these rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding the future plans and potential objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the rapid implementation of any strategically important plan described above. The Company assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION
Contact us:
Jim DiPrima
(888) 979-2675
info@pao.group


Source link

Share.

Leave A Reply